Answers are grounded in this paper and cite their sources.
Background/Objectives: Clarithromycin is a common macrolide antibiotic used to treat bacterial infections, but it can be less effective in clinical settings due to its high level of antibiotic resistance and the bitter taste which makes it less palatable to the patient and thus less effective for compliance. The aim of present study was to synthesize and characterize five new derivatives of clarithromycin and check their antibacterial activity and hydrolytic stability to explore the possibility of modifying clarithromycin as an antibacterial agent and/or as a prodrug. Methods: Rational modification of the structure has been used to synthesize five clarithromycin derivatives and characterized by spectroscopic methods. They were assessed for hydrolytic stability at acidic, mildly acidic and physiological pH (pH 2.2, 5.5 and 7.4). The antibacterial activity was measured in the minimum inhibitory concentration (MIC) and half-maximal inhibitory concentration (IC50) against Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. Results: All of our synthesized derivatives showed antibacterial activity which is species dependent. Derivatives exhibited increased activity against P. aeruginosa when compared to clarithromycin. Of the compounds synthesized, Compound 3 (clarithromycin + 3,5-dinitrobenzoyl chloride) exhibited enhanced activity against all four bacterial species. It was active against S. pneumoniae, P. aeruginosa and S. aureus with IC50 values of 0.27 ± 0.03 µg/mL, 0.32 ± 0.22 µg/mL and 0.15 ± 0.04 µg/mL respectively, and some activity against E. coli. Studies of hydrolysis demonstrated that Compound 3 was not observed to regenerate Clarithromycin under the conditions studied, suggesting that it is not a standard prodrug of Clarithromycin. Conclusions: Clarithromycin derivatives with modified antibacterial activities and increased activity against P. aeruginosa were created by structural modification. Instead of regenerating clarithromycin, Compound 3’s antibacterial activity might be linked to the altered molecule and/or its hydrolysis products. These results encourage additional in vivo, pharmacological, and mechanistic research on this derivative.
No takes yet. Share an insight, caveat, or question.
Qala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: